Hospital Demand to Propel Large Volume Parenteral Market to USD 21 Billion by 2035
New York, Friday, 12 September 2025.
Projected growth in the Large Volume Parenteral market is driven by hospital demand and expanding IV therapy applications, with significant increases expected in the U.S., Europe, and Japan.
Key Drivers of Market Growth
The Large Volume Parenteral (LVP) market is on track to expand from USD 12.5 billion in 2024 to an impressive USD 21.0 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.0% [1]. This growth is predominantly driven by the escalating demand for intravenous therapies across hospitals, which are essential for fluid replacement, parenteral nutrition, medication dilution, and single-dose vaccine delivery [1]. The surge in chronic diseases and an increasing shift towards home infusion practices further bolster market expansion [1].
Regional Market Dynamics
The United States is expected to maintain its position as the largest market for LVPs, with projections indicating growth from USD 3.8 billion in 2024 to USD 6.9 billion by 2035, achieving a CAGR of 5.2% [1]. Europe closely follows, driven by surgical demand and regulatory support for generic medications. In Japan, the market is projected to grow from USD 1.5 billion in 2024 to USD 2.1 billion by 2035, supported by an aging population and a focus on oncology care [1].
Strategic Developments and Industry Impact
Recent strategic developments underscore the industry’s proactive approach to meeting rising demands. In the United States, Baxter has expanded its IV solution production capabilities with a new FDA-compliant sterile line, enhancing supply reliability [1]. In Japan, Otsuka Holdings is collaborating with hospitals to enhance oncology-focused LVP therapies, while Fresenius Kabi has inaugurated a new IV fluid plant in Eastern Europe to address the generic drug demand [1]. These initiatives are crucial in ensuring sustained market growth and addressing regional healthcare needs.
Future Outlook and Challenges
Looking forward, the LVP market is poised to navigate several challenges, including regulatory complexities and the need for technological advancements to improve efficiency in production and distribution [1]. However, the continued emphasis on home healthcare and the development of innovative parenteral solutions are expected to drive market growth. Industry leaders, including B. Braun Melsungen AG, Baxter Healthcare, and Fresenius Kabi, are positioned to capitalize on these opportunities by securing long-term contracts with hospital chains globally [1].